Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. announced that its CEO, Shawn O’Connor, will participate in the 23rd Annual Craig-Hallum Institutional Investor Conference on May 28, 2026, in Minneapolis. Mr. O’Connor plans to hold one-on-one meetings with institutional investors at the event. Simulations Plus is a global leader in model-informed and AI-accelerated drug development.
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
Simulations Plus (Nasdaq: SLP) announced its participation in the 23rd Annual Craig-Hallum Institutional Investor Conference. CEO Shawn O'Connor will host one-on-one meetings with institutional investors on May 28, 2026, in Minneapolis, Minnesota. The company specializes in model-informed and AI-accelerated drug development.
Simulations Plus president sells $16,530 in company stock By Investing.com
Jill Fiedler-Kelly, President of Services Solutions at Simulations Plus (NASDAQ:SLP), recently sold 1,000 shares of company stock for $16,530 via a Rule 10b5-1 trading plan. On the same day, she acquired 1,000 shares by exercising vested employee stock options for $10,050. This transaction occurred amidst predictions of profitability for the company this year, despite it not being profitable over the last twelve months.
Simulations Plus president sells $16,530 in company stock
Jill Fiedler-Kelly, President of Services Solutions at Simulations Plus, Inc. (NASDAQ:SLP), sold 1,000 shares for $16,530 but also acquired 1,000 shares through option exercise for $10,050. The transaction occurs as the stock is considered undervalued by InvestingPro, despite a recent 55% decline in stock price. Simulations Plus also reported strong Q2 2026 earnings, announced collaborations with Nvidia and Lonza/FDA, though TD Cowen lowered its price target due to expected tax rates.
Simulations Plus president sells $16,530 in company stock
Jill Fiedler-Kelly, President of Services Solutions at Simulations Plus, Inc. (NASDAQ:SLP), sold 1,000 shares of company stock for $16,530 at $16.53 per share, significantly above the current stock price. Concurrently, she acquired 1,000 shares through employee stock options at $10.05 per share. The company recently reported strong Q2 FY2026 financials, exceeding forecasts, and is involved in collaborations with Nvidia and the FDA, despite a lowered price target from TD Cowen.
Simulations Plus (SLP) executive exercises options and sells 1,000 shares under 10b5-1 plan
Jill Fiedler-Kelly, President of Services Solutions at Simulations Plus (SLP), exercised options to acquire 1,000 shares at $10.05 each and subsequently sold all 1,000 shares at $16.53 in an open-market transaction. This sale was conducted automatically under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Fiedler-Kelly directly holds 77,817 shares of the company's common stock.
[144] Simulations Plus, Inc. SEC Filing
Simulations Plus, Inc. (SLP) filed a Form 144 Notice of Proposed Sale of Securities with the SEC on May 11, 2026. This filing indicates an intention to sell 1,000 shares of common stock, valued at $16,680.00, acquired through the exercise of stock options on the same date. The securities are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Nicholas Company Inc. Buys 78,854 Shares of Simulations Plus, Inc. $SLP
Nicholas Company Inc. significantly increased its stake in Simulations Plus by 42.9% in the fourth quarter, purchasing 78,854 additional shares to reach a total of 262,712 shares valued at approximately $4.79 million. Despite high institutional ownership and a recent earnings beat, analyst sentiment for Simulations Plus remains cautious, with a "Hold" consensus rating and an average price target of $24.40, while the stock opened at $16.68. The company specializes in advanced modeling and simulation software for the pharmaceutical, biotech, and chemical industries.
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
Simulations Plus and NVIDIA are collaborating to enhance drug discovery through GPU-accelerated, AI-assisted modeling workflows. This partnership aims to integrate Simulations Plus's modeling and simulation software with NVIDIA's computing platforms, facilitating faster and more efficient development of PBPK and QSAR models. The initiative focuses on accelerating the drug development process by leveraging advanced computational power.
Simulations Plus teams with NVIDIA on drug modeling
Simulations Plus has announced a collaboration with NVIDIA to accelerate drug modeling through GPU-accelerated simulation and AI-assisted workflows. This partnership aims to enhance current drug development processes by reducing simulation cycles, automating manual tasks, and enabling more iterative and data-informed approaches. The focus areas include developing next-generation scientific engines, applying AI to refine modeling, and advancing quantitative systems pharmacology, with initial testing showing significant time reductions in QSP modeling.
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
Simulations Plus (SLP) has partnered with Nvidia to enhance its AI drug modeling capabilities, aiming to reduce simulation runtimes by up to 75% for quantitative systems pharmacology (QSP) and pharmacokinetics/pharmacodynamics (PK/PD) applications. Despite this collaboration, Simulations Plus currently faces a weak profile in growth and momentum according to Benzinga Edge, and its shares were trading lower on Wednesday following the announcement. The partnership seeks to allow scientists to explore a wider range of hypotheses and will engage pharmaceutical partners for real-world drug development workflow evaluation.
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
Simulations Plus announced a technical collaboration with NVIDIA to integrate GPU-accelerated simulation and AI-assisted workflows into drug development. This partnership aims to enhance computationally intensive modeling applications across PBPK, PK/PD, and QSP, making drug development processes more iterative and data-informed. The initiative focuses on developing GPU-optimized engines, AI-assisted workflows to reduce manual effort, and advancing quantitative systems pharmacology, with initial testing showing significant time reductions in QSP modeling.
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
Simulations Plus (NASDAQ: SLP) has partnered with NVIDIA Corp (NASDAQ: NVDA) to enhance GPU-accelerated simulation and AI-assisted workflows in drug development, aiming to reduce simulation runtimes by up to 75%. Despite this collaboration, Simulations Plus shares were trading lower, and Benzinga Edge's scorecard indicates a weak profile for the company, particularly in growth and momentum. The partnership will focus on high-complexity modeling use cases, engaging select pharmaceutical partners for real-world evaluation.
NVIDIA tie-up targets up to 75% faster drug-modeling workflows
Simulations Plus (SLP) has partnered with NVIDIA to integrate GPU-accelerated computing and AI into drug development workflows, aiming to significantly speed up and scale modeling and simulation processes. This collaboration will focus on optimizing scientific engines, implementing AI-assisted workflows, and advancing quantitative systems pharmacology, potentially reducing modeling time by up to 75%. The initiative seeks to transform drug development by enabling more robust and data-driven decision-making, shifting from sequential to iterative workflows.
[Form 4] Simulations Plus, Inc. Insider Trading Activity
Simulations Plus, Inc.'s Chief Revenue Officer, John Anthony DiBella II, conducted an open-market sale of 1,000 shares of common stock at $14.98 per share. This transaction was executed automatically under a pre-arranged Rule 10b5-1 trading plan. Following the sale, DiBella directly holds 88,140 shares of the company's common stock.
Simulations Plus (SLP) insiders sell 15,000 shares in planned trade
Simulations Plus, Inc. (SLP) directors and principal shareholders, Walter and Virginia Woltosz, sold 15,000 shares of common stock at an average price of $15.13 per share. This transaction, totaling $226,950, was an open-market sale conducted automatically under a pre-defined Rule 10b5-1 trading plan. After the sale, they directly held 3,267,800 shares, indicating that this sale
[144] Simulations Plus, Inc. SEC Filing
This article details a Form 144 SEC filing by Simulations Plus, Inc. (SLP) on May 4, 2026, indicating a proposed sale of 15,000 shares of common stock acquired by founders in 1996. The aggregate market value of these shares is $223,650, which will be sold via Morgan Stanley Smith Barney LLC on NASDAQ. The filing has a neutral impact and sentiment according to StockTitan.
Do Options Traders Know Something About Simulations Plus Stock We Don't?
The article highlights unusual options market activity for Simulations Plus (SLP), specifically the high implied volatility of the June 18, 2026 $22.50 Call option, suggesting investors anticipate a significant price movement. Despite this, analysts are bearish on SLP, with a Zacks Rank #4 (Sell) and recent downward revisions to earnings estimates. This divergence may indicate a potential trading opportunity for options traders, particularly those who sell premium.
Director Sharlene Evans receives 2,117 SLP shares in equity grant
Simulations Plus, Inc. director Sharlene Evans was granted 2,117 shares of common stock on May 1, 2026, as part of her independent director compensation under the company's 2021 Equity Incentive Plan. This equity grant, valued at $0.00 per share, increased her direct holdings to 17,173 shares. The transaction was reported in a Form 4 filing, indicating an acquisition rather than a market purchase.
Simulations Plus (SLP) director awarded 2,117 shares as equity compensation
Simulations Plus (SLP) director Daniel L. Weiner was awarded 2,117 shares of common stock as equity compensation under the company's 2021 Equity Incentive Plan. This grant increases his direct holdings to 16,547 shares and was issued at no cash cost per share, as reported in a Form 4 SEC filing. The transaction was a stock grant for independent director compensation, not an open-market purchase or sale.
Director at Simulations Plus (SLP) receives 2,117-share stock grant
Simulations Plus director Walter S. Woltsoz received a grant of 2,117 shares of common stock as independent director compensation, with no cash cost. This grant, issued under the company's 2021 Equity Incentive Plan, increases his direct holdings to 3,282,800 shares. The transaction, reported in a Form 4 SEC filing, was not an open-market purchase.
AI in Predictive Toxicology Research Report 2026 Featuring
The "AI in Predictive Toxicology Market Report 2026" forecasts significant growth, reaching $2.29 billion by 2030 from $0.83 billion in 2026, driven by AI adoption, cloud platforms, and genomics integration. Key trends include multi-omics integration and strategic collaborations, with North America dominating and Asia-Pacific showing the fastest growth. Companies like Certara and Schrodinger are leading advancements in chemical safety assessments and drug toxicity prediction.
AI in Predictive Toxicology Research Report 2026 Featuring
The AI in predictive toxicology market is expected to grow significantly, reaching $2.29 billion by 2030, driven by increased AI adoption for chemical safety, pharmaceutical R&D, and cloud-based platforms. Key companies like Certara Inc. and Schrodinger Inc. are leading advancements in the field, with North America dominating the market and Asia-Pacific showing the fastest growth. The report highlights strategic collaborations and technological integrations as crucial for innovation in drug discovery and chemical safety assessments.
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from Brokerages
Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus "Hold" rating from ten brokerages, with an average 12-month price target of $24.40. Despite beating Q1 earnings and revenue estimates, the company reported a negative net margin of 77.96% and a negative P/E ratio, raising profitability concerns. Institutional investors hold approximately 78% of the company's stock, which opened at $14.56.
Latest SLP News - Simulations Plus Announces Quarterly Cash Di...
Simulations Plus (Nasdaq: SLP) recently announced a quarterly cash dividend of $0.06 per share, payable on November 2, 2020, to shareholders of record by October 26, 2020. The company, a leader in biosimulation and AI-enabled drug development, also extended a partnership with a large pharmaceutical company to enhance high-throughput PBPK capabilities within its ADMET Predictor® platform. These announcements highlight the company's financial practices and continuous advancements in its core technology, serving the pharmaceutical and biotechnology sectors.
Simulations Plus shares drop over 12% premarket as Q3 revenue forecast misses expectations
Simulations Plus (SLP) shares fell over 12% premarket due to its third-quarter revenue forecast missing average analyst estimates, projecting between $15.8 million and $16.0 million against an expected $17.0 million. Despite this, the company reiterated its full-year revenue outlook of $64.0 million to $67.0 million. The company reported better-than-expected Q2 results, with adjusted diluted EPS of $0.18 and revenue of $16.9 million, surpassing estimates.
Simulations Plus partners with Lonza and FDA on drug formulation research
Simulations Plus Inc. has announced a research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop a predictive framework for amorphous solid dispersion drug products. This partnership aims to integrate in vitro testing with mechanistic modeling to predict the in vivo performance of complex oral formulations, potentially reducing the need for extensive clinical bioequivalence studies. Simulations Plus will utilize its DDDPlus and GastroPlus platforms to support virtual bioequivalence assessments, backed by FDA funding.
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf
Simulations Plus Inc. (SLP) has announced a research partnership with Lonza Group and the FDA to develop a predictive framework for evaluating amorphous solid dispersion (ASD) drug products. This collaboration aims to streamline drug development by accurately forecasting in vivo results, potentially reducing the need for expensive clinical bioequivalence studies. While Simulations Plus shows strong financial strength and profitability with a GF Score™ of 78, investors should consider its declining growth margins and recent insider selling activity.
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Simulations Plus (SLP) has announced a research partnership with Lonza Group and the FDA to develop a predictive framework for evaluating the in vivo performance of amorphous solid dispersion (ASD) drug products. This collaboration aims to streamline drug development and potentially reduce the need for expensive clinical bioequivalence studies. SLP, with a strong GF Score™ of 78 and robust financial strength, shows promising long-term potential despite some challenges in growth as indicated by declining margins and recent insider selling.
Simulations Plus partners with Lonza and FDA on drug formulation research
Simulations Plus Inc. has announced a research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop a predictive framework for amorphous solid dispersion drug products. This initiative aims to integrate in vitro testing with mechanistic modeling to forecast in vivo performance of complex oral formulations, potentially reducing the need for extensive clinical bioequivalence studies. Despite a recent loss, analysts anticipate profitability this year for Simulations Plus, which also boasts a strong balance sheet.
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus, Lonza, and the U.S. FDA are collaborating on a funded research initiative to develop and validate a mechanistic, predictive framework for amorphous solid dispersion (ASD) drug products. This partnership aims to integrate advanced in vitro systems with mechanistic modeling to improve predictions of in vivo performance, reduce the need for extensive clinical bioequivalence studies, and support regulatory decision-making for complex oral formulations. The goal is to accelerate the development of high-impact therapies by creating more efficient and scientifically rigorous pathways.
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus successfully completed its 2026 Spring School, a global training initiative focused on model-informed drug development (MIDD). The program attracted over 1,400 scientists from more than 65 countries, reflecting a growing demand for expertise in modeling and simulation in drug development. This initiative underscores the company's commitment to education and strengthening the scientific foundation of the industry.
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus, Inc. successfully completed its 2026 Spring School, a global training initiative in model-informed drug development (MIDD). The program saw over 1,400 scientists from 65+ countries participate, highlighting the growing demand for MIDD expertise. This initiative reinforces the company's commitment to education and strengthening the scientific foundation of the drug development industry.
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus, Inc. successfully completed its 2026 Spring School, a global training initiative focused on model-informed drug development (MIDD). The program attracted over 1,400 participants from 65+ countries, highlighting the increasing adoption of model-informed workflows in drug development. This initiative underscores the company's commitment to educating the next generation of scientists and expanding the use of these advanced methodologies.
Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development
Simulations Plus Inc (SLP) is advancing AI-enabled modeling in drug development, collaborating with large pharmaceutical companies to integrate AI into their workflows rather than as a standalone solution. The company recently surpassed financial expectations for fiscal Q2 2026, reporting increased EPS and revenue for both its software and services segments. Simulations Plus aims to use its AI solutions to enhance efficiency, speed up drug development, and reduce costs for pharmaceutical and biotechnology companies.
Simulations Plus Reports Strong Fiscal Second Quarter Growth
Simulations Plus Inc. (SLP) reported strong fiscal second-quarter results, exceeding market expectations with an EPS of $0.35 and total revenue of $24.3 million, an 8% year-over-year increase. The growth was driven by increased adoption of AI-enabled modeling in drug development, with software sales accounting for 60% of revenue. The company projects full fiscal year 2026 revenue between $79 million and $82 million and adjusted EPS between $0.75 and $0.85, emphasizing its strategy of integrating AI responsibly into pharmaceutical workflows.
John Anthony Dibella II Sells 1,000 Shares of Simulations Plus (NASDAQ:SLP) Stock
John Anthony Dibella II, CRO of Simulations Plus (NASDAQ:SLP), sold 1,000 shares of the company's stock on April 15th at an average price of $13.37, reducing his stake by 1.11%. This insider sale occurred despite Simulations Plus exceeding Q1 earnings and revenue expectations. Analysts generally maintain a "Hold" rating on the stock, which has seen a significant price decline despite the positive earnings report.
Simulations Plus (SLP) CRO sells 1,000 shares via Rule 10b5-1 plan
Simulations Plus, Inc.'s Chief Revenue Officer, John Anthony DiBella II, sold 1,000 shares of common stock at $13.37 per share on April 15, 2026. This transaction was executed automatically under a pre-arranged Rule 10b5-1 trading plan, and he now directly holds 89,140 shares. The sale, valued at $13,370, highlights routine insider activity planned in advance to reduce the risk of insider trading accusations.
Simulations Plus Q2 Earnings Call Highlights
Simulations Plus (NASDAQ: SLP) reported strong Q2 fiscal 2026 results, with revenue of $24.3 million exceeding guidance and adjusted EPS of $0.35. The company saw growth in both software and services segments, supported by improving market conditions and increased client activity. While AI collaborations with large pharma partners are underway, significant financial contributions from these initiatives are not expected until fiscal year 2027.
120,101 Shares in Simulations Plus, Inc. $SLP Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL acquired a new position of 120,101 shares in Simulations Plus (NASDAQ:SLP) during Q3, valued at approximately $1.81 million. Despite the company beating Q2 earnings expectations, its FY2026 EPS guidance was cut, leading several analysts to trim ratings and price targets, resulting in a consensus "Hold" rating. Simulations Plus specializes in modeling and simulation software for pharmaceutical, biotechnology, and chemical industries.
Simulations Plus (NASDAQ: SLP) boosts Q2 profit but cuts EPS outlook
Simulations Plus (NASDAQ: SLP) reported a strong second quarter of fiscal 2026, with revenue rising 8% to $24.3 million and net income growing to $4.5 million, or $0.22 diluted EPS. Despite the improved profitability and increased gross margin to 66%, the company cut its full-year adjusted diluted EPS outlook from $1.03–$1.10 to $0.75–$0.85. This reduction is primarily due to a higher anticipated effective tax rate of 23–25%, while revenue and adjusted EBITDA margin guidance remain unchanged.
Simulations Plus (SLP) Quarterly Profit Tests Bearish Narratives On Earnings Decline
Simulations Plus (SLP) reported mixed Q2 2026 results with quarterly profit but trailing twelve-month losses. While revenue growth is modest at 5.1% per year, bears point to a 65.4% decline in earnings over five years and acquisition-related issues. Bulls anticipate higher growth from AI and new verticals, and the stock trades below its DCF fair value but above sector P/S multiples.
What's Going On With Simulations Plus Stock Friday?
Simulations Plus Inc. reported better-than-expected Q2 fiscal 2026 results, with sales up 8% to $24.29 million and adjusted earnings of 35 cents per share, surpassing consensus estimates. Despite strong growth in software and services revenue, the company lowered its full-year adjusted earnings guidance while affirming its sales outlook. Analysts note that favorable market trends, regulatory guidance on new approach methodologies, and growing interest in AI are benefiting Simulations Plus.
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2026 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP) reported strong Q2 2026 results, exceeding revenue guidance with $24.3 million, driven by growth in both Software and Services segments. The company highlighted its transition to an AI-driven biosimulation ecosystem and announced strategic collaborations with three major pharmaceutical companies to integrate AI workflows into drug development. While acknowledging broader market caution, Simulations Plus expressed confidence in its building momentum and its strategic positioning in leveraging AI to enhance drug discovery and development, with anticipated AI monetization beginning in fiscal year 2027.
Simulations Plus (SLP) grows profit on higher margins and strong cash flow
Simulations Plus (SLP) reported solid Q2 fiscal 2026 results, with quarterly revenue rising 8% to $24.3 million and net income increasing 48% to $4.5 million, due to higher margins and efficient services. For the first six months, revenue reached $42.7 million (up 3%) and net income climbed 59% to $5.2 million, supported by robust cash flow. The company is heavily reinvesting in R&D, earmarking 18% of revenue for an integrated, cloud-enabled, AI-driven modeling ecosystem, while maintaining a strong balance sheet with over $41.8 million in cash and short-term investments.
Simulations Plus reports $24.3M revenue and $0.22 diluted EPS for quarter
Simulations Plus reported total revenue of $24.3 million for the three months ended February 28, 2026, marking an 8% year-over-year increase, alongside a diluted EPS of $0.22. The company's net income rose by 48% to $4.535 million, driven by strong growth in both software and services, and improved operating results due to higher gross margins. This performance was attributed to lower software amortization, increased services efficiency, and strategic investments in R&D focusing on cloud-enabled modeling and AI.
Simulations Plus: Fiscal Q2 Earnings Snapshot
Simulations Plus Inc. reported fiscal Q2 earnings of $4.5 million, or 22 cents per share, topping Street forecasts with revenue of $24.3 million. Adjusted earnings were 35 cents per share. The company anticipates full-year earnings between 75 cents and 85 cents per share, and revenue ranging from $79 million to $82 million.
Simulations Plus jumps on earnings beat, sees AI boosting biosimulation outlook
Simulations Plus (SLP) stock surged after reporting an earnings beat and raising its full-year revenue guidance. The company's CEO highlighted tailwinds including a strong balance sheet, returning pharma/biotech R&D spending, and the potential of AI to enhance biosimulation, contributing to positive projections for the future.
Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
Simulations Plus (SLP) reported strong second-quarter fiscal 2026 results, with adjusted earnings of 35 cents per share and revenues of $24.3 million, both exceeding expectations. The growth was primarily driven by continued demand for its drug discovery and development software, leading to an 18% increase in backlog and an 18% jump in shares pre-market. Despite a strong operational performance, the company lowered its adjusted EPS guidance for fiscal 2026 while reaffirming its revenue view.
Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
Simulations Plus (SLP) reported strong second-quarter fiscal 2026 results, with adjusted EPS of 35 cents exceeding estimates by 29% and a revenue increase of 8% year-over-year to $24.3 million. This growth was primarily driven by strong demand in its software segment, particularly in drug discovery and development tools, leading to an 18% increase in backlog and a rise in share price by 18% pre-market. Despite strong performance, the company cut its fiscal 2026 EPS outlook to 75-85 cents, although it reaffirmed its revenue guidance of $79 million to $82 million.
